In their classification system, Tervaert et al. 1 divide diabetic nephropathy into four classes based on the presence of what they consider to be increasingly serious glomerular lesions ().The ...

The global burden of diabetic nephropathy increased from 1990 to 2021, and is projected to continue increasing to 2050, ...

Immunoglobulin A (IgA) nephropathy is a condition that causes a certain type of protein to build up in your kidneys. It progresses differently in everyone. Your kidneys might still work well years ...

Immunoglobulin A (IgA) nephropathy, also called Berger’s disease, is an autoimmune disease that affects your kidneys. IgA is an antibody. Antibodies are proteins made by your immune system.

The global IgA nephropathy disease treatment market is poised for substantial growth, with projections indicating a robust CAGR of 20.8% during the forecast period from 2022 to 2028. This growth is ...

The following is a summary of “Construction and validation of a predictive model for malignant tumors in patients with ...

The following is a summary of “Bucillamine-induced membranous nephropathy versus primary membranous nephropathy: comparing pathological features and kidney prognosis,” published in the March 2025 ...

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...

Dublin, Feb. 28, 2025 (GLOBE NEWSWIRE) -- The "Diabetic Nephropathy - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The clinical trial ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA ...